TEMTempus AI, Inc.
$70.98-20% 1Y
$70.98
$42.3752 weeks$103.25
The financials
Tempus AI, Inc. by the numbers
Tempus AI, Inc. (TEM) reported revenue of $382M in Q2 2026 (quarter ended Jun 30, 2026), up 22% from the same quarter a year earlier. That came with net income of $5.6M (1.5% of revenue). For the full year FY2025, revenue was $1.27B (+83% year on year) and net income −$245M. Its largest product in Q2 2026 was Clinical Order at $264M, 69% of the disclosed total, well ahead of Insights Product at 20%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $382M | $315M | +22% |
| Operating income | −$76M | −$62M | n/a |
| Net income | $5.6M | −$43M | to a profit |
| Diluted EPS | $0.03 | −$0.25 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Clinical Order | $264M | 69% |
| Insights Product | $78M | 20% |
| Genomics Product | $25M | 6.5% |
| Trials Product | $9.0M | 2.4% |
| Next Product | $6.3M | 1.6% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $382.3M (+9.9%)
Insights Product grew +36% year on yearTrials Product -8.2% year on year
Segment Latestquarter on quarteryear on year
- Clinical Order$264.4M$264.4Mquarter on quarter +10%year on year +19%+10%+19%
- Insights Product$77.7M$77.7Mquarter on quarter +9.0%year on year +36%+9.0%+36%
- Genomics Product$24.9M$24.9Mquarter on quarter +14%year on year +24%+14%+24%
- Trials Product$9.0M$9.0Mquarter on quarter -9.1%year on year -8.2%-9.1%-8.2%
- Next Product$6.3M$6.3Mquarter on quarter +11%year on year +11%+11%+11%
On our screens:Most shorted stocks
Health Information Services
Ranks #20 of 20 by RyuScore